Global market for Diabetes therapies and Diagnostics to be worth 51.2 billion in 2015
Posted Aug 02 2010 12:11am
Diabetes Therapies & Diagnostics: Global Markets report ( http://www.bharatbook.com/detail.asp?id=144947&rt=Diabetes-Therapies-Diagnostics ) which gives the global market value for diabetes therapies and diagnostics is an estimated $38 billion in 2010, but is expected to increase to $51.2 billion in 2015, for a 5-year compound annual growth rate (CAGR) of 6.1%. The largest segment of the market, insulin products (including administration devices), is estimated to be worth $16.4 billion in 2010, and is expected to increase at a CAGR of 6.1% to reach $22 billion in 2015. Monitoring devices and accessories, the second-largest segment, is expected to reach $14.1 billion in 2015, after increasing from the 2010 estimate of $11.3 billion at a CAGR of 4.5%. The fastest-growing segment, oral hypoglycemic drugs, is projected to increase at a CAGR of 8%, increasing from an estimated $10.3 billion in 2010 to $15.1 billion in 2015.
The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly. Type 1 diabetes is an autoimmune disease; it appears in childhood, is lifelong and currently must be treated with insulin. Type 2 diabetes typically appears in middle age. It is linked to obesity and therefore is more prevalent in developed countries with relatively affluent lifestyles, sedentary occupations and dietary overindulgence. Monitoring devices include blood glucose monitors and various types of accessories such as lancing devices used to draw the droplets of blood required for glucose measurement.
It is widely recognized that the prevalence of the commonest type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 DM are also on the increase, although to a less spectacular degree.
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, both in global terms and analyzed by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.